Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether adding a new drug, dasatinib, to imatinib is
safe, and whether the combination of the two drugs will help decrease the number of cells
that contain the Philadelphia chromosome.